{
  "docId": "019de076-9103-7399-8bed-9b1b1a8b182a",
  "docSlug": "93c36ca1f8977b3a70b566ce0ab54138",
  "documentTitle": "argenx SE | Investor Conference Presentation Deck | 27 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 27,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "key_messages",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a stacked bar/arrow hybrid to illustrate growth. The data points are 6,000 (US patients), 17,000 (RoW TAM), and 31,000 (US TAM).",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-9103-7399-8bed-9b1b1a8b182a/10",
  "deckHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a",
  "deckJsonHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a.json",
  "deckAnchorHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.45,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Growth arrows showing patient and TAM metrics",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7d4150b-c634-483e-9059-6c5541a8668b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.11,
        "y": 0.94
      },
      "kind": "legend",
      "text": "US, RoW argenx markets (exc. China), Global",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78a3b429-8984-4e3e-8962-33e623ed7b1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.4,
        "x": 0.55,
        "y": 0.15
      },
      "kind": "list",
      "text": "Growing VYVGART share: US J-Code, PFS development, China NRDL. Expanding VYVGART TAM: Label-enabling trials, Phase 3b, Geographic expansion. Growing MG market: Targeted biologics.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85b2ffbc-cdd2-4218-8f88-97f1e07d9bc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.55,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "*As of Q3 2023 Financial Results. Based on argenx market research.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "670c34e3-dfcf-4996-9b41-f6e903147ba0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Innovation Builds Autoimmune Market Opportunities",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa7be47f-fd10-4bd8-aa82-54ad6e1f748e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "10300344-3ff1-4b97-95a5-8662d641a2aa",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Rising Success",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "Highlighting commercial execution and market opportunities",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 5,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "f381209b-40fa-4c32-8920-66d6dea883b8",
      "evidence": "Discussion of innovation horizons and market opportunities",
      "position": 0,
      "objective": "Why now is the time for argenx SE's innovation",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}